• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tissue Plasminogen Activator in Critically Ill Adults with COVID-19.

作者信息

Douin David J, Shaefi Shahzad, Brenner Samantha K, Gupta Shruti, Park Isabel, Wright Franklin L, Mathews Kusum S, Chan Lili, Al-Samkari Hanny, Orfanos Sarah, Radbel Jared, Leaf David E

机构信息

University of Colorado School of Medicine Aurora, Colorado.

Beth Israel Deaconess Medical Center Boston, Massachusetts.

出版信息

Ann Am Thorac Soc. 2021 Nov;18(11):1917-1921. doi: 10.1513/AnnalsATS.202102-127RL.

DOI:10.1513/AnnalsATS.202102-127RL
PMID:33872546
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8641829/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4613/8641829/c0f5f45806e0/AnnalsATS.202102-127RLf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4613/8641829/c0f5f45806e0/AnnalsATS.202102-127RLf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4613/8641829/c0f5f45806e0/AnnalsATS.202102-127RLf1.jpg

相似文献

1
Tissue Plasminogen Activator in Critically Ill Adults with COVID-19.组织型纤溶酶原激活剂用于重症 COVID-19 成年患者
Ann Am Thorac Soc. 2021 Nov;18(11):1917-1921. doi: 10.1513/AnnalsATS.202102-127RL.
2
Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.美国 COVID-19 导致的急性呼吸窘迫综合征（ARDS）中组织型纤溶酶原激活剂（tPA）的补救性应用：一项马尔可夫决策分析。
World J Emerg Surg. 2020 Apr 20;15(1):29. doi: 10.1186/s13017-020-00305-4.
3
Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial.组织型纤溶酶原激活剂治疗重症新型冠状病毒肺炎成人患者：一项前瞻性随机临床试验
Thromb Res. 2022 Aug;216:125-128. doi: 10.1016/j.thromres.2021.12.003. Epub 2021 Dec 7.
4
Insights into Fibrinogen-Mediated COVID-19 Hypercoagubility in Critically Ill Patients.深入了解 COVID-19 危重症患者纤维蛋白原介导的高凝状态。
J Neurosurg Anesthesiol. 2022 Jan 1;34(1):136-140. doi: 10.1097/ANA.0000000000000812.
5
Point-of-care diagnosis and monitoring of fibrinolysis resistance in the critically ill: results from a feasibility study.危重病患者纤维蛋白溶解抵抗的即时诊断和监测：一项可行性研究的结果。
Crit Care. 2023 Feb 10;27(1):55. doi: 10.1186/s13054-023-04329-5.
6
Impaired fibrinolysis in critically ill COVID-19 patients.危重症 COVID-19 患者的纤维蛋白溶解功能受损。
Br J Anaesth. 2021 Mar;126(3):590-598. doi: 10.1016/j.bja.2020.12.010. Epub 2020 Dec 9.
7
Rescue therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: A case series.组织型纤溶酶原激活剂治疗严重 COVID-19 相关急性呼吸窘迫综合征的抢救治疗：病例系列研究。
J Trauma Acute Care Surg. 2020 Sep;89(3):453-457. doi: 10.1097/TA.0000000000002786.
8
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.急性呼吸窘迫综合征（ARDS）中的纤维蛋白溶解异常和溶栓药物治疗 COVID-19 的多功能性。
J Thromb Haemost. 2020 Jul;18(7):1548-1555. doi: 10.1111/jth.14872. Epub 2020 Jun 3.
9
Injection of Recombinant Tissue Plasminogen Activator into Extracorporeal Membrane Oxygenators Postpones Oxygenator Exchange in COVID-19.在 COVID-19 患者中，将重组组织型纤溶酶原激活剂注入体外膜肺氧合机会延迟氧合器更换。
ASAIO J. 2022 Aug 1;68(8):1017-1023. doi: 10.1097/MAT.0000000000001733. Epub 2022 May 16.
10
Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study.COVID-19 危重症患者的凝血、血管内皮功能和纤溶生物标志物：一项单中心前瞻性纵向研究。
J Thromb Haemost. 2021 Jun;19(6):1546-1557. doi: 10.1111/jth.15327. Epub 2021 May 1.

引用本文的文献

1
Fibrinolytic system and COVID-19: From an innovative view of epithelial ion transport.纤维蛋白溶解系统与 COVID-19：从上皮细胞离子转运的创新视角看。
Biomed Pharmacother. 2023 Jul;163:114863. doi: 10.1016/j.biopha.2023.114863. Epub 2023 May 9.
2
Systemic reduced-dose alteplase for diffuse pulmonary thrombi in a COVID-19 patient.COVID-19患者弥漫性肺血栓的全身性低剂量阿替普酶治疗
Clin Case Rep. 2023 Mar 15;11(3):e7116. doi: 10.1002/ccr3.7116. eCollection 2023 Mar.
3
Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trial.

本文引用的文献

1
Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space.关于重组组织型纤溶酶原激活剂在新型冠状病毒肺炎中应用的观察性研究表明生理死腔减少。
ERJ Open Res. 2020 Oct 5;6(4). doi: 10.1183/23120541.00455-2020. eCollection 2020 Oct.
2
Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID-19: Study design of the phase IIa STARS trial.阿替普酶治疗严重急性呼吸综合征冠状病毒2/新型冠状病毒肺炎所致呼吸衰竭的研究：IIa期STARS试验的研究设计
Res Pract Thromb Haemost. 2020 Aug 19;4(6):984-996. doi: 10.1002/rth2.12395. eCollection 2020 Aug.
3
治疗性抗凝对机械通气的新冠肺炎患者气体交换的影响：COVID-HEP试验的二次分析
Thromb Res. 2023 Apr;224:13-16. doi: 10.1016/j.thromres.2023.02.003. Epub 2023 Feb 10.
4
Pathophysiological mechanisms of thrombosis in acute and long COVID-19.急性 COVID-19 和长新冠中的血栓形成的病理生理学机制。
Front Immunol. 2022 Nov 16;13:992384. doi: 10.3389/fimmu.2022.992384. eCollection 2022.
5
Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS.新型冠状病毒肺炎相关急性呼吸窘迫综合征中溶栓药物的药物治疗考量
J Intensive Care. 2022 Jul 30;10(1):38. doi: 10.1186/s40560-022-00625-4.
6
The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1.COVID-19 中纤溶反应不佳是由高水平 PAI-1 决定的。
J Thromb Haemost. 2022 Oct;20(10):2394-2406. doi: 10.1111/jth.15806. Epub 2022 Jul 21.
7
MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study.组织纤溶酶原激活剂（阿替普酶）用于新型冠状病毒肺炎严重呼吸衰竭的多中心研究（MUST COVID）：一项回顾性队列研究。
Res Pract Thromb Haemost. 2022 Mar 21;6(2):e12669. doi: 10.1002/rth2.12669. eCollection 2022 Feb.
8
Fibrinolytic therapy for COVID-19: a review of case series.COVID-19的纤维蛋白溶解疗法：病例系列综述
Acta Pharmacol Sin. 2022 Aug;43(8):2168-2170. doi: 10.1038/s41401-021-00827-w. Epub 2021 Dec 10.
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US.
与美国 2019 年冠状病毒病危重症患者死亡相关的因素。
JAMA Intern Med. 2020 Nov 1;180(11):1436-1447. doi: 10.1001/jamainternmed.2020.3596.
4
Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: Scientific rationale and review.用于难治性新型冠状病毒肺炎急性呼吸窘迫综合征的纤溶治疗：科学原理与综述
Res Pract Thromb Haemost. 2020 Jun 12;4(4):524-531. doi: 10.1002/rth2.12357. eCollection 2020 May.
5
Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.非裔美国人 COVID-19 患者的肺部和心脏病理学：来自新奥尔良的尸检系列。
Lancet Respir Med. 2020 Jul;8(7):681-686. doi: 10.1016/S2213-2600(20)30243-5. Epub 2020 May 27.
6
Rescue therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: A case series.组织型纤溶酶原激活剂治疗严重 COVID-19 相关急性呼吸窘迫综合征的抢救治疗：病例系列研究。
J Trauma Acute Care Surg. 2020 Sep;89(3):453-457. doi: 10.1097/TA.0000000000002786.
7
Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis.新冠肺炎患者 ICU 中的高凝状态：血栓弹力描记图结果和其他止血参数报告。
J Thromb Haemost. 2020 Jul;18(7):1738-1742. doi: 10.1111/jth.14850. Epub 2020 Jun 24.
8
Prognostic value of vasoactive-inotropic score following continuous flow left ventricular assist device implantation.连续血流左心室辅助装置植入术后血管活性-正性肌力评分的预后价值。
J Heart Lung Transplant. 2019 Sep;38(9):930-938. doi: 10.1016/j.healun.2019.05.007. Epub 2019 May 24.
9
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.依达赛珠单抗治疗与因子 Xa 抑制剂相关出血的完整研究报告。
N Engl J Med. 2019 Apr 4;380(14):1326-1335. doi: 10.1056/NEJMoa1814051. Epub 2019 Feb 7.
10
Validation of the Vasoactive-Inotropic Score in Pediatric Sepsis.血管活性药物评分在儿童脓毒症中的验证
Pediatr Crit Care Med. 2017 Aug;18(8):750-757. doi: 10.1097/PCC.0000000000001191.